Among patients with non–muscle-invasive bladder cancer, neoadjuvant mitomycin demonstrated favorable safety. Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with ...

In December 2022, the company reported findings from the Phase IIb OPTIMA II trial of UGN-102 (mitomycin) to treat LG-IR-NMIBC. "UroGen begins subject dosing in Phase III bladder cancer drug trial ...

Two recent analyses provide new insight into the clinical efficacy of BCG versus chemotherapy with mitomycin C in intermediate-risk and high-risk bladder cancer. BCG immunotherapy showed a ...

UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for UGN-301 in bladder cancer.

High-risk, non-muscle-invasive bladder cancer is defined as any transitional ... been shown to be superior to monthly maintenance with mitomycin C, the induction of cytokines with a single dose ...

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...

The high recurrence rate and the unpredictability of the progression pattern of bladder cancer have led to the widespread use of intravesical therapy as a supplement to TUR. Superficial bladder ...

UGN-102 is UroGen’s sustained-release formulation of mitomycin being developed for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

UroGen’s shares drop 20% as the FDA raises concerns about the trial design for UGN-102 bladder cancer treatment.